Skip to content

Kluwer Patent Blog

Kluwer Patent Blog
  • Facebook
  • X
  • LinkedIn
  • YouTube

Opposition

Opposition systems are closely related to the patent granting procedure, and offer third parties an opportunity to oppose the grant of a patent, by giving notice of opposition to the granting authorities. In some states, there is a pre-grant opposition procedure, in others it is a post-grant procedure. Reasons for opposition may be that the invention is not new, does not involve an inventive step, is not susceptible of industrial application, is excepted from patentability, that the patent does not disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art, or that the subject-matter of the patent extends beyond the content of the application as filed, for instance.

Biologics, Case Law, EPC, Opposition

Sequence analysis/MEDICAL BIOSYSTEMS, European Patent Office (EPO Board of Appeal), 23 March 2009

Bart van Weezenbeek/March 23, 2009

When the transitional provisions for EPC 2000 are silent, the Board has to establish which legal text is applicable. In that case the Board has to take into account that it is undesirable to use both different versions of the EPC over a prolonged period of time and that there is no indication that the…

Continue reading

Posts navigation

«‹456
Wolters Kluwer

Go to posts on

(Compulsory) license (Cross-border) jurisdiction (Indirect) infringement Amendments Biologics Brexit Case Law Chemical Engineering Damages Denmark Enforcement EPC EPO EPO Decision Equivalents European Union Exceptions to patentability Extent of Protection France FRAND Germany Infringement Injunction Inventive step Italy Litigation Netherlands Novelty Opposition Patents Pharma Pharmaceutical patent Procedure Revocation Scope of protection SEP Spain SPC Sufficiency of disclosure Switzerland Unitary Patent United Kingdom United States of America UPC Validity
VAEPC-2024-edVissers Annotated European Patent Convention 2024 EditionKaisa Suominen, Nina Ferara, Peter de Lange, Andrew Rudge€ 105
Annotated-PCTAnnotated PCTMalte Köllner€ 160
AI-GovernanceAI Governance and Liability in Europe: A Primer Ceyhun Necati Pehlivan, Nikolaus Forgó, Peggy Valcke€ 150

Number 3 in Top 10 Pharma Patent Blogs To Follow in 2022!

Pharma Patent Blogs

Blog Contributors

  • Brian Cordery
    Bristows
  • Rik Lambers
    Brinkhof
  • Rachel Mumby
    Bristows
  • Daniela Ampollini
    Trevisan & Cuonzo
  • Thorsten Bausch
    Hoffmann Eitle
  • Enrico Bonadio
    City, University of London
  • John Collins
    Clayton Utz
  • Matthieu Dhenne
    Dhenne Avocats
  • Simon Holzer
    MLL Legal Ltd.
  • Adam Lacy
    Hoffmann Eitle
  • Vaishali Mittal
    Anand and Anand
  • Miquel Montañá
    Clifford Chance
  • Roberto Rodrigues Pinho
    RNA Law
  • Alexa von Uexküll
    Vossius & Partner
  • Anders Valentin
    Bugge Valentin

Kluwer IP Law News Alert

Stay informed on Intellectual Property law & developments

Search Posts

RSS feeds

Summary Feed Article Feed

Related Sites

  • Kluwer IP Law
  • Kluwer Copyright Blog
  • Kluwer Trademark Blog
  • Regulating for Globalization Blog
  • Author Portal
Kluwer Logo

About us

  • About Kluwer Patent Blog
  • Kluwer IP Law
  • Kluwer Law International
  • E-store
  • Authors

Legal policy

  • User Agreement and Disclaimer
  • Editorial Policy & Guidelines
  • Privacy Policy and Use of Cookies

Contact

  • General Information
Back to top